Is there an association between liraglutide use and female breast cancer in a real-world setting?
Donnie Funch,1 Kathleen Mortimer,1 Ling Li,1 Heather Norman,1 Atheline Major-Pedersen,2 Anne Helene Olsen,3 Margit S Kaltoft,4 David D Dore1,5 1Optum Epidemiology, Boston, MA, USA; 2Global Safety, Novo Nordisk A/S, Copenhagen, Denmark; 3Epidemiology, Novo Nordisk A/S, Copenhagen, Denmark; 4Global De...
Main Authors: | Funch D, Mortimer K, Li L, Norman H, Major-Pedersen A, Olsen AH, Kaltoft MS, Dore DD |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-11-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/is-there-an-association-between-liraglutide-use-and-female-breast-canc-peer-reviewed-article-DMSO |
Similar Items
-
Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
by: Funch D, et al.
Published: (2021-06-01) -
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01) -
Liraglutide for weight management: a critical review of the evidence
by: A. Mehta, et al.
Published: (2017-03-01) -
Effect of liraglutide 3.0 mg on eating behavior in patients with obesity
by: O. V. Logvinova, et al.
Published: (2021-05-01) -
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
by: Christiane Lundegaard Haase, et al.
Published: (2021-08-01)